keyword
MENU ▼
Read by QxMD icon Read
search

hyperthermic intraperitoneal chemotherapy

keyword
https://www.readbyqxmd.com/read/28228199/the-efficacy-of-dextran-40-as-a-venous-thromboembolism-prophylaxis-strategy-in-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#1
Jason M Foster, Richard Sleightholm, Duncan Watley, Steven Wahlmeier, Asish Patel
The incidence of venous thromboembolism (VTE) in peritoneal malignancies can approach 30 to 50 per cent without prophylaxis. Prophylaxis in cytoreductive surgeries (CRS) presents a challenge to preoperative heparin-based therapy because of an increased risk of coagulopathy and potential for bleeding. Herein, we report the large series of CRS and hyperthermic intraperitoneal chemotherapy receiving dextran-40 prophylaxis. Retrospective chart review of peritoneal malignancies patients undergoing CRS at University of Nebraska Medical Center identified 69 individuals who received dextran-40 between 2010 and 2013...
February 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28224367/novel-treatment-with-intraperitoneal-moc31pe-immunotoxin-in-colorectal-peritoneal-metastasis-results-from-the-immunopeca-phase-1-trial
#2
Ida S Frøysnes, Yvonne Andersson, Stein G Larsen, Ben Davidson, Janne-Merete Torset Øien, Kari Hauge Olsen, Karl-Erik Giercksky, Lars Julsrud, Øystein Fodstad, Svein Dueland, Kjersti Flatmark
BACKGROUND: MOC31PE immunotoxin was developed to rapidly kill cells expressing the tumor-associated epithelial cell adhesion molecule, which is highly expressed in colorectal cancer. Although cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may offer long-term survival to patients with peritoneal metastasis from colorectal cancer (PM-CRC), most patients experience disease relapse and novel therapeutic options are needed. On this basis, MOC31PE is being developed as a novel therapeutic principle to target PM-CRC...
February 21, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28222738/are-there-intra-operative-hemodynamic-differences-between-the-coliseum-and-closed-hipec-techniques-in-the-treatment-of-peritoneal-metastasis-a-retrospective-cohort-study
#3
Cristina Rodríguez Silva, Francisco Javier Moreno Ruiz, Inmaculada Bellido Estévez, Joaquin Carrasco Campos, Alberto Titos García, Manuel Ruiz López, Ivan González Poveda, Jose Antonio Toval Mata, Santiago Mera Velasco, Julio Santoyo Santoyo
BACKGROUND: Although two main methods of intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) are currently accepted, the superiority of one over the other has not yet been demonstrated. The purpose of this study was to determine whether there are hemodynamic and temperature differences between patients who received HIPEC in two different techniques, open versus closed abdomen. METHODS: This retrospective study was conducted in our center between 2011-2015 in 30 patients who underwent surgery for peritoneal carcinomatosis secondary to colorectal cancer, in whom cytoreduction and HIPEC were performed by the Coliseum (15) or closed techniques (15)...
February 21, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28222307/survival-of-patients-with-colorectal-peritoneal-metastases-is-affected-by-treatment-disparities-among-hospitals-of-diagnosis-a-nationwide-population-based-study
#4
Koen P Rovers, Geert A Simkens, Pauline A Vissers, Valery E Lemmens, Victor J Verwaal, Andre J Bremers, Marinus J Wiezer, Jacobus W Burger, Patrick H Hemmer, Henk Boot, Wilhelmina M van Grevenstein, Wilhelmus J Meijerink, Arend G Aalbers, Cornelis J Punt, Pieter J Tanis, Ignace H de Hingh
BACKGROUND: In the Netherlands, surgery for peritoneal metastases of colorectal cancer (PMCRC) is centralised, whereas PMCRC is diagnosed in all hospitals. This study assessed whether hospital of diagnosis affects treatment selection and overall survival (OS). METHODS: Between 2005 and 2015, all patients with synchronous PMCRC without systemic metastases were selected from the Netherlands Cancer Registry. Treatment was classified as cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), systemic therapy or other/no treatment...
February 17, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28219391/pulmonary-toxicity-after-intraperitoneal-mitomycin-c-a-case-report-of-a-rare-complication-of-hipec
#5
Melissa L Abel, George Kokosis, Dan G Blazer
BACKGROUND: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has become a common treatment approach for disseminated appendiceal neoplasms. Systemic absorption of intraperitoneal chemotherapeutics may lead to drug-induced toxicity, most commonly neutropenia. Mitomycin C has been the most commonly used chemotherapeutic in HIPEC for the past several decades. CASE PRESENTATION: Here, we describe a rare pulmonary complication secondary to intraperitoneal administration of mitomycin C...
February 20, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28211128/staged-intraperitoneal-brachytherapy-and-hyperthermic-intraperitoneal-chemotherapy-in-an-adolescent-novel-anesthetic-challenges-for-pediatric-anesthetists
#6
Andrew D Weatherall, Tristan R Bennett, Mark Lovell, Winnie Fung, Jonathan de Lima
Newer techniques that have found a place in cancer management in adults are offered far less commonly in pediatric patients. We present a case of a patient with recurrent Wilms' tumor managed with a novel combination of cytoreductive surgery, intraperitoneal brachytherapy, and subsequent hyperthermic intraperitoneal chemotherapy. Each stage presents challenges that the pediatric anesthetist is unlikely to have faced before. Such cases require flexibility and thorough planning to manage the combination of major surgery, remote anesthesia with brachytherapy and hyperthermic chemotherapy with its potential for metabolic derangement, significant fluid shifts, analgesic care, and potential exposure of staff to cytotoxic agents...
February 17, 2017: Paediatric Anaesthesia
https://www.readbyqxmd.com/read/28210074/second-look-surgery-plus-hyperthermic-intraperitoneal-chemotherapy-for-patients-with-colorectal-cancer-at-high-risk-of-peritoneal-carcinomatosis-does-it-really-save-lives
#7
EDITORIAL
Delia Cortes-Guiral, Dominique Elias, Pedro Antonio Cascales-Campos, Alfredo Badía Yébenes, Ismael Guijo Castellano, Ana Isabel León Carbonero, José Ignacio Martín Valadés, Jesus Garcia-Foncillas, Damian Garcia-Olmo
The treatment of peritoneal carcinomatosis (PC) of colorectal origin with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has a 5-year recurrence-free or cure rate of at least 16%, so it is no longer labeled as a fatal disease, and offers prolonged survival for patients with a low peritoneal carcinomatosis index. Metachronous PC of colorectal origin is so predictable that there is a model which has been used to successfully determine the individual risk of each patient. Patients at risk are clearly identified; those with the highest risk have small peritoneal nodules present in the first surgery (70% probability of developing PC), ovarian metastases (60%), perforated tumor onset or intraoperative tumor rupture (50%)...
January 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28209329/prognostic-factors-of-hemorrhagic-complications-after-oxaliplatin-based-hyperthermic-intraperitoneal-chemotherapy-toward-routine-preoperative-dosage-of-von-willebrand-factor
#8
J-B Delhorme, L Sattler, F Severac, E Triki, I Gross, B Romain, S Rohr, L Grunebaum, C Brigand
BACKGROUND: Oxaliplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC-ox) induces specific morbidity with hemorrhagic complications (HC). The aim of this study was to identify preoperative, intraoperative and postoperative HC predictive factors after HIPEC-ox. METHODS: A prospective single center study that included all consecutive patients treated with curative-intent HIPEC-ox, whatever the origin of peritoneal disease, was conducted. All patients underwent systematic blood tests exploring primary hemostasis and endothelial activation before surgical incision (D0) and on postoperative days 2 (POD2) and 5 (POD5)...
February 2, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28203422/colobronchial-fistula-the-pathogenesis-clinical-presentations-diagnosis-and-treatment
#9
Jinbo Zhao, Nan Ma, Zhengwei Zhao, Jie Lei, Qiang Lu, Feng Tian, Yongan Zhou, Yong Han, Xiaofei Li
BACKGROUND: Colobronchial fistula (CBF) is rare and easy to be delayed in clinic. There is no systemic study about this disease. The pathogenesis, clinical presentations, diagnosis and treatment of CBF were analyzed in this study. METHODS: The clinical data from 37 cases of CBF, which included one case in our institute and the other 36 cases in literature from January 1960 to August 2016, were reviewed and analyzed. The etiology, clinical presentations, diagnostic and therapeutic methods, and outcomes were summarized...
January 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28181257/limited-synchronous-hepatic-resection-does-not-compromise-peri-operative-outcomes-or-survival-after-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#10
Akshat Saxena, Sarah J Valle, Winston Liauw, David L Morris
INTRODUCTION: There is uncertainty about whether hepatic resection (HR) combined with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is effective. METHODS: Nine hundred and thirty-five consecutive CRS/HIPEC procedures were performed between 1996 and 2016 of which 132(14%) involved concomitant HR. Peri-operative complications were graded according to the Clavien-Dindo Classification. The association of concomitant HR with 19 peri-operative outcomes and overall survival (OS) was assessed using univariate and multivariate analyses...
February 9, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28168311/impact-of-laparotomy-and-intraperitoneal-hyperthermic-instillation-lihi-on-the-oxaliplatin-pharmacokinetics-after-intravenous-administration-in-wistar-rats
#11
María Isabel Mas-Fuster, Amelia Ramon-Lopez, Javier Lacueva, Antonio Compañ, Patricio Más-Serrano, Ricardo Nalda-Molina
PURPOSE: In peritoneal metastasis condition, the fact that most of the disease is limited to the peritoneal cavity laid the foundations for a surgical treatment, including intraperitoneal hyperthermic chemotherapy (HIPEC). The aim of this study was to evaluate the impact of the surgical procedures implied in open HIPEC technique, referred to laparotomy procedures followed by an intraperitoneal hyperthermic instillation (LIHI) on oxaliplatin tissue distribution and elimination. To delimit the influence of this procedure alone, oxaliplatin was administered as an intravenous (iv) bolus in both groups...
February 6, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28160138/pharmacodynamics-of-oxaliplatin-derived-platinum-compounds-during-hyperthermic-intraperitoneal-chemotherapy-hipec-an-emerging-aspect-supporting-the-rational-design-of-treatment-protocols
#12
Markus W Löffler, Heiko Schuster, Anne Zeck, Nicolas Quilitz, Jürgen Weinreich, Alexander Tolios, Sebastian P Haen, Philipp Horvath, Stefan Löb, Hans-Georg Rammensee, Ingmar Königsrainer, Alfred Königsrainer, Stefan Beckert
BACKGROUND: Hyperthermic intraperitoneal chemotherapy (HIPEC) is used to treat peritoneal surface malignancies with application of cytostatic drugs such as oxaliplatin (OX) after cytoreductive surgery. Despite its increased use, evidence for optimal drug dosage, and notably duration of HIPEC, is scarce. METHODS: In this study, OX distribution was comprehensively assessed in nine patients during HIPEC (300 mg OX/m(2) body surface area in Physioneal solution for 30 min)...
February 3, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28142288/update-on-clinical-trials-in-colorectal-cancer-peritoneal-metastasis
#13
Amandine Pinto, Clarisse Eveno, Marc Pocard
BACKGROUND/PURPOSE: Peritoneal metastases (PM) arising from colorectal cancer (CRC) can be treated using cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in select patients. OBJECTIVE: To review clinical trials that were reported during the 10(th) International Congress on Peritoneal Surface Malignancies and dedicated to the treatment of CRC-PM. METHODS: Ten clinical trials were presented at the 10(th) PSOGI meeting in November 2016 in Washington DC...
January 31, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28138878/preoperative-platelet-lymphocyte-ratio-is-an-independent-prognostic-marker-and-superior-to-carcinoembryonic-antigen-in-colorectal-peritoneal-carcinomatosis-patients-undergoing-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#14
Tiffany Sin Hui Bong, Grace Hwei Ching Tan, Claramae Chia, Khee Chee Soo, Melissa Ching Ching Teo
OBJECTIVE: The aim of this study was to examine the prognostic significance of preoperative inflammatory-based indices, platelet-lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR), and carcinoembryonic antigen (CEA) in predicting overall survival (OS) in patients with colorectal peritoneal carcinomatosis (CPC) treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: Sixty patients with pathologically confirmed CPC treated with CRS and HIPEC between 2003 and 2015 were included...
January 30, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28133187/-stage-iv-gastric-cancer-with-positive-peritoneal-washing-cytology-or-peritoneal-dissemination-was-successfully-treated-with-gastrectomy-and-hyperthermic-intraperitoneal-chemotherapy-hipec-followed-by-systemic-chemotherapy-a-report-of-two-cases
#15
Tsuyoshi Yamaguchi, Satoshi Murata, Sachiko Kaida, Reiko Ohtake, Katsushi Takebayashi, Hiroshi Yamamoto, Toru Miyake, Hiroya Akabori, Hiromichi Sonoda, Tsuyoshi Mori, Tomoharu Shimizu, Shigeyuki Naka, Suzuko Moritani, Ryoji Kushima, Masaji Tani
Survival of Stage IV gastric cancer is poor. We report 2 cases of Stage IV gastric cancer with positive peritoneal washing cytology or peritoneal dissemination that were successfully treated with gastrectomy and hyperthermic intraperitoneal chemotherapy( HIPEC)followed by systemic chemotherapy. Case 1: A 59-year-old woman. She was diagnosed with advanced gastric cancer and underwent gastrectomy with HIPEC. Her peritoneal washing cytology was positive during the gastrectomy. After the surgery, she underwent chemotherapy consisting of 8 courses of combination S-1 plus CPT-11 and 19 courses of PTX...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133016/-clinical-evaluation-of-hyperthermic-intraperitoneal-chemotherapy-hipec-in-colorectal-cancer-patients-at-high-risk-of-peritoneal-recurrence
#16
Hiroyuki Ohta, Tomoharu Shimizu, Hiromichi Sonoda, Tomoyuki Ueki, Toru Miyake, Eiji Mekata, Yoshihiro Endo, Tsuyoshi Yamaguchi, Sachiko Kaida, Katsushi Takebayashi, Satoshi Murata, Hiroshi Yamamoto, Hiroya Akabori, Shigeyuki Naka, Masaji Tani
PURPOSE: We herein report the clinical outcomes of hyperthermic intraperitoneal chemotherapy(HIPEC)in patients at high risk of colorectal peritoneal metastasis. PATIENTS AND METHODS: We enrolled 21 patients with advanced colorectal cancer who were received HIPEC between 2009 and 2014. Retrospectively, we evaluated the short-term and long-term outcomes of these cases. RESULTS: We performed HIPEC for 12 patients with primary cancer and 9 with recurrent cancer...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28124576/current-status-and-future-prospects-of-clinical-trials-on-crs-hipec-for-gastric-cancer-peritoneal-metastases
#17
Zhong-He Ji, Kai-Wen Peng, Yang Yu, Xin-Bao Li, Yutaka Yonemura, Yang Liu, Paul H Sugarbaker, Yan Li
PURPOSE: There is no standard treatment for peritoneal metastases (PM) from gastric cancer (GC). The aim of this review is to evaluate the clinical trials on cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for GC PM. MATERIALS AND METHODS: The published clinical trials on CRS + HIPEC for GC PM are critically evaluated, and survival and safety are the primary endpoints. In addition, the registered ongoing clinical trials are summarized...
January 26, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28124449/patients-experiences-of-their-everyday-life-14%C3%A2-months-after-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-a-qualitative-follow-up-study
#18
Christine Leo Swenne, Eva Jangland, Erebouni Arakelian
BACKGROUND: Patients with peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have a long recovery process. AIM: To describe patients' experiences of their everyday lives after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. METHOD: A follow-up study with a qualitative, descriptive design. Data were collected by individual, in-depth telephone interviews with 16 patients who had been treated for peritoneal carcinomatosis 14 months earlier at a university hospital in Sweden...
January 25, 2017: Scandinavian Journal of Caring Sciences
https://www.readbyqxmd.com/read/28114231/brief-report-about-the-role-of-hyperthermic-intraperitoneal-chemotherapy-in-a-prospective-randomized-phase-3-study-in-recurrent-ovarian-cancer-from-spiliotis-et-al
#19
Philipp Harter, Alexander Reuss, Jalid Sehouli, Luis Chiva, Andreas du Bois
A published so-called phase 3 study regarding HIPEC in ovarian cancer raised multiple questions. This commentary focusses on the weakness of the publication and discusses this in detail.
February 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28112791/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-peritoneal-metastases-of-colorectal-origin
#20
N F M Kok, I H J T de Hingh
No abstract text is available yet for this article.
January 23, 2017: British Journal of Surgery
keyword
keyword
84002
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"